Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Stomach Neoplasms
Conditions
Stomach Neoplasms, Gastroesophageal Junction Neoplasms
Trial Timeline
Oct 1, 2010 → Aug 1, 2017
NCT ID
NCT01234324About Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine
Epirubicin, Cisplatin, Capecitabine, Panitumumab + Epirubicin, Cisplatin, Capecitabine is a phase 2 stage product being developed by Amgen for Stomach Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT01234324. Target conditions include Stomach Neoplasms, Gastroesophageal Junction Neoplasms.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01234324 | Phase 2 | Completed |
Competing Products
20 competing products in Stomach Neoplasms